[go: up one dir, main page]

MX2019005090A - Derivados de piridazina como moduladores de receptor gamma huerfano relacionado a acido retinoico (rorc). - Google Patents

Derivados de piridazina como moduladores de receptor gamma huerfano relacionado a acido retinoico (rorc).

Info

Publication number
MX2019005090A
MX2019005090A MX2019005090A MX2019005090A MX2019005090A MX 2019005090 A MX2019005090 A MX 2019005090A MX 2019005090 A MX2019005090 A MX 2019005090A MX 2019005090 A MX2019005090 A MX 2019005090A MX 2019005090 A MX2019005090 A MX 2019005090A
Authority
MX
Mexico
Prior art keywords
rorc
modulators
retinoic acid
gamma receptor
receptor related
Prior art date
Application number
MX2019005090A
Other languages
English (en)
Other versions
MX391145B (es
Inventor
Lee Wendy
Bodil Van Niel Monique
Hurley Christopher
Fauber Benjamin
Rene Olivier
Gobbi Alberto
Ward Stuart
Killen Jonathan
Cridland Andrew
Gancia Emanuela
Winship Paul
M Bronner Sarah
J Crawford James
CYR Patrick
ZBIEG Jason
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019005090A publication Critical patent/MX2019005090A/es
Publication of MX391145B publication Critical patent/MX391145B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula I: (ver Fórmula) o sales de los mismos farmacéuticas, en donde m, n, p, q A, B, R1, R2, R3, R4, R5, R6 y R7 son como se definen en la presente. También se describen métodos para elaborar los compuestos y usar los compuestos para el tratamiento enfermedades inflamatorias tales como artritis.
MX2019005090A 2016-11-01 2017-10-31 Derivados de piridazina como moduladores de receptor gamma huerfano relacionado a acido retinoico (rorc). MX391145B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662415905P 2016-11-01 2016-11-01
PCT/EP2017/077931 WO2018083105A1 (en) 2016-11-01 2017-10-31 Pyridazine derivatives as rorc modulators

Publications (2)

Publication Number Publication Date
MX2019005090A true MX2019005090A (es) 2019-09-02
MX391145B MX391145B (es) 2025-03-21

Family

ID=60201586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005090A MX391145B (es) 2016-11-01 2017-10-31 Derivados de piridazina como moduladores de receptor gamma huerfano relacionado a acido retinoico (rorc).

Country Status (10)

Country Link
US (1) US11008312B2 (es)
EP (1) EP3535255A1 (es)
JP (1) JP2019533000A (es)
KR (1) KR20190070985A (es)
CN (1) CN110225907A (es)
BR (1) BR112019008821A8 (es)
CA (1) CA3042317A1 (es)
MX (1) MX391145B (es)
RU (1) RU2757571C2 (es)
WO (1) WO2018083105A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3883651A1 (en) * 2018-11-19 2021-09-29 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
KR20240056718A (ko) 2021-08-10 2024-04-30 아이에프엠 듀, 인크. Sting 활성과 연합된 상태를 치료하기 위한 화합물 및 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
JP4787321B2 (ja) * 2005-07-05 2011-10-05 エフ．ホフマン−ラ ロシュ アーゲー ピリダジン誘導体
KR101760158B1 (ko) * 2010-07-29 2017-07-20 아스텔라스세이야쿠 가부시키가이샤 축환 피리딘 화합물
JP6378774B2 (ja) * 2013-11-05 2018-08-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 自己免疫疾患を処置するためのＲＯＲｃモジュレーターとしての５，６，７，８−テトラヒドロ−５，８−メタノシンノリン誘導体
TW201620884A (zh) * 2014-01-10 2016-06-16 赫孚孟拉羅股份公司 作為ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
WO2016177686A1 (en) * 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag PYRIDAZINE DERIVATIVES AS RORc MODULATORS

Also Published As

Publication number Publication date
BR112019008821A8 (pt) 2020-02-04
CN110225907A (zh) 2019-09-10
EP3535255A1 (en) 2019-09-11
WO2018083105A1 (en) 2018-05-11
RU2019115791A (ru) 2020-12-03
US20190263794A1 (en) 2019-08-29
RU2757571C2 (ru) 2021-10-18
CA3042317A1 (en) 2018-05-11
JP2019533000A (ja) 2019-11-14
KR20190070985A (ko) 2019-06-21
RU2019115791A3 (es) 2020-12-17
MX391145B (es) 2025-03-21
US11008312B2 (en) 2021-05-18

Similar Documents

Publication Publication Date Title
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
EA201691491A1 (ru) Арильные и гетероарильные эфиры в качестве модуляторов ror-гамма
CY1122916T1 (el) Νεες ενωσεις ως ρυθμιστες ror γαμμα
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
ECSP18010535A (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
UY35818A (es) Composiciones y métodos para modular los receptores x farnesoides
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
CO2017006174A2 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
MX2017016413A (es) Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
CR20170496A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CL2020001047A1 (es) Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma.
CL2019003515A1 (es) Compuestos heteroaromáticos como inhibidores de vanina.
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
MX2019003310A (es) Inhibidores de dopamina-b-hidroxilasa.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).